New hope for lung cancer: smart drug combo targets hidden DNA signals
NCT ID NCT06951646
First seen Mar 18, 2026 · Last updated May 15, 2026 · Updated 7 times
Summary
This study tests whether adding a new drug (ivonescimab) to standard chemotherapy can help people with advanced non-small cell lung cancer who had a good long-term response to initial immunotherapy but still have cancer DNA in their blood. About 70 participants will be randomly assigned to receive either the new combination or standard treatment. The goal is to see if this approach delays cancer progression and improves outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Army Medical Center (Daping Hospital)
NOT_YET_RECRUITINGChongqing, China
Contact
-
Changsha Central Hospital
NOT_YET_RECRUITINGChangsha, China
Contact
-
Faculty of Medicine, The Chinese University of Hong Kong
NOT_YET_RECRUITINGHong Kong, China
Contact
-
Guiyang Public Health Clinical Center
NOT_YET_RECRUITINGGuiyang, China
Contact
-
Hubei Cancer Hospital
NOT_YET_RECRUITINGWuhan, China
Contact
-
Hunan Cancer Hospital
NOT_YET_RECRUITINGChangsha, 410011, China
Contact
-
Kiang Wu Hospital, Macao
NOT_YET_RECRUITINGMacao, China
Contact
-
Liaoning Cancer Hospital and Institute
NOT_YET_RECRUITINGShenyang, China
Contact
-
Renmin Hospital of Wuhan University
NOT_YET_RECRUITINGWuhan, China
Contact
-
Shanxi Bethune Hospital
NOT_YET_RECRUITINGTaiyuan, China
Contact
-
The First Affiliated Hospital of Guangxi Medical University
NOT_YET_RECRUITINGNanning, China
Contact
-
The First Affiliated Hospital of Nanchang University
NOT_YET_RECRUITINGNanchang, China
Contact
-
The First Affiliated Hospital of Xinxiang Medical University
NOT_YET_RECRUITINGXinxiang, China
Contact
-
The First Hospital of Changsha
NOT_YET_RECRUITINGChangsha, China
Contact
-
The Second Xiangya Hospital of Central South University
RECRUITINGChangsha, 410011, China
Contact
-
The Third Hospital of Changsha
NOT_YET_RECRUITINGChangsha, 410011, China
Contact
-
The Third Xiangya Hospital of Central South University
NOT_YET_RECRUITINGChangsha, China
Contact
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NOT_YET_RECRUITINGWuhan, China
Contact
-
Xiangya Hospital of Central South University
NOT_YET_RECRUITINGChangsha, 410011, China
Contact
-
Zhuzhou Central Hospital
NOT_YET_RECRUITINGZhuzhou, China
Contact
Conditions
Explore the condition pages connected to this study.